News

Pozen is now close to the receipt of a $20 million milestone windfall from GlaxoSmithKline, which is due to be paid to Pozen upon FDA approval of the

PV-10 is the company’s lead cancer agent and is being evaluated for safety and preliminary efficacy in 20 subjects with Stage III metastatic melanoma, which is the most

The drug candidate prevents all types and strains of influenza virus from entering the airway epithelial cells, including avian influenza as well as para-influenza viruses. It aims at

Benign prostatic hyperplasia (BPH) can restrict the flow of urine, resulting in urine retention, which can cause weakening of the bladder wall and the inability to empty the

Sinusitis is one of the most common conditions seen by primary care physicians, and according to the National Ambulatory Medical Care Survey, is the fifth most common condition

The drug is designed to concurrently inhibit the same molecular targets of breast cancer drug, Herceptin, and colon cancer drug, Erbitux. There is currently no single drug on

Three confirmed cases of multifocal leukoencephalopathy (PML), a rare demyelinating disease of the central nervous system, had previously been reported in patients treated with Tysabri (natalizumab), which Biogen

Previously, the efficacy of asthma drugs has been judged via measures of airflow obstruction, which the company suggests do not tell the whole story in terms of asthma

The first patients will commence treatment in early August at the Royal North Shore Hospital in Sydney and the Sydney Haematology and Oncology Clinics and further clinical centers